Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2013 1
2014 1
2016 1
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein.
Ferretti AP, Kula T, Wang Y, Nguyen DMV, Weinheimer A, Dunlap GS, Xu Q, Nabilsi N, Perullo CR, Cristofaro AW, Whitton HJ, Virbasius A, Olivier KJ Jr, Buckner LR, Alistar AT, Whitman ED, Bertino SA, Chattopadhyay S, MacBeath G. Ferretti AP, et al. Among authors: olivier kj jr. Immunity. 2020 Nov 17;53(5):1095-1107.e3. doi: 10.1016/j.immuni.2020.10.006. Epub 2020 Oct 20. Immunity. 2020. PMID: 33128877 Free PMC article.
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
Reynolds JG, Geretti E, Hendriks BS, Lee H, Leonard SC, Klinz SG, Noble CO, Lücker PB, Zandstra PW, Drummond DC, Olivier KJ Jr, Nielsen UB, Niyikiza C, Agresta SV, Wickham TJ. Reynolds JG, et al. Among authors: olivier kj jr. Toxicol Appl Pharmacol. 2012 Jul 1;262(1):1-10. doi: 10.1016/j.taap.2012.04.008. Epub 2012 Apr 21. Toxicol Appl Pharmacol. 2012. PMID: 22676972
Electrolyte and Metabolic Disturbances in Ebola Patients during a Clinical Trial, Guinea, 2015.
van Griensven J, Bah EI, Haba N, Delamou A, Camara BS, Olivier KJ, De Clerck H, Nordenstedt H, Semple MG, Van Herp M, Buyze J, De Crop M, Van Den Broucke S, Lynen L, De Weggheleire A; Ebola-Tx Consortium. van Griensven J, et al. Among authors: olivier kj. Emerg Infect Dis. 2016 Dec;22(12):2120-7. doi: 10.3201/eid2212.161136. Emerg Infect Dis. 2016. PMID: 27869610 Free PMC article.
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.
Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, Razlog M, Jiao Y, Harms BD, Olivier KJ Jr, Schoeberl B, Nielsen UB, Lugovskoy AA. Fitzgerald JB, et al. Among authors: olivier kj jr. Mol Cancer Ther. 2014 Feb;13(2):410-25. doi: 10.1158/1535-7163.MCT-13-0255. Epub 2013 Nov 26. Mol Cancer Ther. 2014. PMID: 24282274